#Epidemiology and phylogenomic characterisation of two distinct #mpox #outbreaks in #Kinshasa, #DRC, involving a new #subclade Ia lineage: a retrospective, observational study

Summary

Background

Clade I monkeypox virus is endemic in DR Congo. We aim to describe the epidemiological trends of the cocirculating subclades Ia and Ib mpox outbreaks in Kinshasa, DR Congo.

Methods

This retrospective observational study included suspected and laboratory-confirmed mpox cases reported between Jan 1, 2023, and Oct 31, 2024, in Kinshasa. Skin lesion swabs or blood samples were collected as part of a routine countrywide mpox surveillance programme. To confirm the diagnosis of mpox, all samples were tested at the Institut National de Recherche Biomédicale (INRB) using real-time PCR. Whole-genome sequencing was conducted for phylogenomic analysis and assessment of APOBEC3 type mutations. Samples that remained unassigned to subclade Ia or Ib after whole-genome sequencing and real-time PCR were labelled as an unknown subclade.

Findings

As part of routine disease surveillance, 1479 suspected mpox cases were reported in Kinshasa. Samples were collected from 1314 suspected mpox cases and tested by PCR at the INRB. 440 (34%) of 1314 suspected cases had PCR confirmed mpox, with the first confirmed mpox case detected on Aug 18, 2023. 262 (60%) of 440 cases were male, 172 (39%) were female, and six (1%) were unknown, and the median age was 26 years (IQR 19–34). The epidemiological curve suggests two distinct periods during the 2023–24 outbreaks in Kinshasa. Between Aug 18, 2023, and June 30, 2024 (period 1), 218 suspected mpox cases underwent investigation and 24 (11%) were PCR confirmed as mpox; all cases were identified as subclade Ia. After a decline in suspected and confirmed cases in early 2024, the first confirmed subclade Ib mpox case in Kinshasa was reported on July 1, 2024. Between July 1 and Oct 31, 2024 (period 2), 1096 suspected mpox cases were reported and 416 (38%) were PCR confirmed as mpox. In-depth epidemiological case investigations during period 1 identified three small, self-limiting transmission chains between August and September, 2023. Case investigation data were available for 127 cases with PCR confirmed mpox, including clinical symptom data available for 61 (64%) of 95 with subclade Ia. The most commonly reported symptoms were fever (49 [80%] of 61) and skin rash (48 [79%]). The most common lesion locations were genital or anorectal (35 [64%] of 55 cases with available data). Case investigation data were available for 32 cases with subclade Ib mpox, including clinical symptom data available for 21 (66%) with subclade Ib. The most commonly reported symptoms were skin rash (18 [86%] of 21) and fever (12 [57%]). Genital or anorectal involvement was reported in 13 (68%) of 19 cases with available lesion location data. Genomic analysis shows five separate self-limiting clusters of subclade Ia (group II sampled from August, 2023, to August, 2024) and two larger clusters (occurring from July, 2024, to October, 2024, in period 2) belonging to subclade Ia (group II) and subclade Ib. 32 (68%) of 47 mutations for subclade Ia cluster outbreak and 28 (72%) of 39 mutations for subclade Ib outbreak were consistent with APOBEC3 driven changes.

Interpretation

Sustained human-to-human transmission occurred after repeated self-limiting introductions of subclade Ia documented since 2023, which has cocirculated with subclade Ib in Kinshasa from July, 2024. Increased APOBEC3 driven changes in the new subclade Ia lineage support a shift towards human-to-human transmission. These findings reveal important changes in mpox transmission dynamics and suggests that any monkeypox virus subclade has the potential to cause sustained human outbreaks when favourable transmission conditions are met.

Source: Lancet, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00294-6/abstract?rss=yes

____

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...

ETIDIOH - NEW

Search This Blog